Apogee Therapeutics, Inc. (APGE) insider trading.
In Q3 2026, insiders at Apogee Therapeutics, Inc. reported 21 non-derivative transactions on 15 Forms 3, 4 and 5: 0 open-market purchases and 3 sales worth $4.1M.
- Transactions
- 21
- Purchases (P)
- 0
- Sales (S)
- 3
- Net shares, P minus S
- -31,000
- Insiders
- 9
- Last filed
- 2026-09-03
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Dambkowski Carl | Officer · Chief Medical Officer | 7 | 0 | 2 |
| Fairmount Funds Management LLC / Harwin Peter Evan / Kiselak Tomas / Fairmount Healthcare Fund II L.P. | Director | 3 | 0 | 0 |
| Henderson Michael Thomas | Director, Officer · Chief Executive Officer | 3 | 0 | 1 |
| Henderson Jane | Officer · Chief Financial Officer | 2 | 0 | 0 |
| Fairmount Healthcare Fund II L.P. / Kiselak Tomas / Fairmount Funds Management LLC / Harwin Peter Evan | Director | 2 | 0 | 0 |
| Shah Nimish P | Director | 1 | 0 | 0 |
| Fox Jennifer A. | Director | 1 | 0 | 0 |
| Jones William A Jr | Director | 1 | 0 | 0 |
| McKenna Mark C. | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-03 | Fairmount Funds Management LLC / Harwin Peter Evan / Kiselak Tomas / Fairmount Healthcare Fund II L.P. | D (D) | 51,166 | — | 0 | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC / Harwin Peter Evan / Kiselak Tomas / Fairmount Healthcare Fund II L.P. | D (D) | 340,855 | — | 0 | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC / Harwin Peter Evan / Kiselak Tomas / Fairmount Healthcare Fund II L.P. | D (D) | 51,166 | — | 0 | Form 4 |
| 2026-09-03 | Shah Nimish P | D (D) | 1,750,000 | $135.11 | 0 | Form 4 |
| 2026-09-03 | Henderson Michael Thomas | D (D) | 920,941 | — | 0 | Form 4 |
| 2026-09-03 | Henderson Jane | D (D) | 158,371 | — | 0 | Form 4 |
| 2026-09-03 | Fox Jennifer A. | D (D) | 34,824 | — | 0 | Form 4 |
| 2026-09-03 | Dambkowski Carl | D (D) | 167,123 | — | 0 | Form 4 |
| 2026-09-03 | Jones William A Jr | D (D) | 34,824 | — | 0 | Form 4 |
| 2026-09-03 | McKenna Mark C. | D (D) | 20,000 | — | 0 | Form 4 |
| 2026-09-02 | Dambkowski Carl | D (D) | 1,375 | $135.06 | 167,123 | Form 4 |
| 2026-08-07 | Fairmount Healthcare Fund II L.P. / Kiselak Tomas / Fairmount Funds Management LLC / Harwin Peter Evan | M (A) | 31,838 | $17 | 330,485 | Form 4 |
| 2026-08-07 | Fairmount Healthcare Fund II L.P. / Kiselak Tomas / Fairmount Funds Management LLC / Harwin Peter Evan | M (A) | 10,370 | $43.85 | 340,855 | Form 4 |
| 2026-08-05 | Dambkowski Carl | M (A) | 4,125 | $22.86 | 173,998 | Form 4 |
| 2026-08-05 | Dambkowski Carl | S (D) | 5,500 | $134.17 | 168,498 | Form 4 |
| 2026-07-24 | Henderson Jane | G (D) | 15,000 | $0 | 158,371 | Form 4 |
| 2026-07-14 | Dambkowski Carl | G (D) | 8,000 | $0 | 169,873 | Form 4 |
| 2026-07-10 | Henderson Michael Thomas | G (D) | 75,046 | $0 | 920,941 | Form 4 |
| 2026-07-08 | Henderson Michael Thomas | S (D) | 20,000 | $133.63 | 995,987 | Form 4 |
| 2026-07-01 | Dambkowski Carl | S (D) | 5,500 | $132.74 | 177,873 | Form 4 |
| 2026-07-01 | Dambkowski Carl | M (A) | 4,125 | $22.86 | 183,373 | Form 4 |
Transaction codes in this quarter
Get APGE insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1974640&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · Apogee Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Apogee Therapeutics, Inc. (APGE)?
In Q3 2026, insiders at Apogee Therapeutics, Inc. reported 21 non-derivative transactions on 15 Forms 3, 4 and 5: 0 open-market purchases and 3 sales worth $4.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Apogee Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/apge.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.